Creative Planning
RXRX icon

Creative Planning’s Recursion Pharmaceuticals RXRX Stock Holding History

Creative Planning’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,000
Closed -$598 – 4073
2025
Q3 		$598 Buy
+2,000
New +$10.5K ﹤0.01% 3899

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Creative Planning's RXRX Position: Q2 2026 in Review

Creative Planning reduced its Recursion Pharmaceuticals (RXRX) stake by 28% in Q2 2026, selling an estimated $87.4K and leaving 67,955 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #3717.

Creative Planning first reported a position in RXRX in Q3 2023 and has held it in 8 quarters since. The position peaked at $289K in Q1 2026. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Creative Planning held 67,955 shares of Recursion Pharmaceuticals worth $249K as of Q2 2026.
  • Creative Planning sold 26,253 Recursion Pharmaceuticals shares in Q2 2026, an estimated $87.4K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3717 holding.
  • Creative Planning first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
  • Creative Planning's Recursion Pharmaceuticals position peaked at $289K in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.